Author

Karl Wassmann

Observed names: K. Wassmann, Wassmann, Karl

Observed institutions: Harvard University, University of Pittsburgh, Dana-Farber Cancer Institute, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai

OpenAlex ID: A5033035766

A whole-blood RNA transcript-based prognostic model in men with castration-resistant prostate cancer: a prospective study

2012 · Robert W Ross, Matthew D Galsky, et al. · The Lancet Oncology · 111

Whole-blood RNA transcript-based models can predict clinical response in two large independent clinical studies of patients with advanced melanoma treated with the checkpoint inhibitor, tremelimumab

2017 · Philip Friedlander, Karl Wassmann, et al. · Journal for ImmunoTherapy of Cancer · 56

A whole-blood RNA transcript-based gene signature is associated with the development of CTLA-4 blockade-related diarrhea in patients with advanced melanoma treated with the checkpoint inhibitor tremelimumab

2018 · Philip Friedlander, Kevin Wood, et al. · Journal for ImmunoTherapy of Cancer · 48

Blood mRNA Expression Profiling Predicts Survival in Patients Treated with Tremelimumab

2014 · Yvonne Saenger, Jay Magidson, et al. · Clinical Cancer Research · 48

Transcriptome Profiling of Whole Blood Cells Identifies PLEK2 and C1QB in Human Melanoma

2011 · Yuchun Luo, Steven Robinson, et al. · PLoS ONE · 47

Blood-Based Biomarkers of Aggressive Prostate Cancer

2012 · Men Long Liong, Chun Ren Lim, et al. · PLoS ONE · 44

The Role of Proxy Genes in Predictive Models: An Application to Early Detection of Prostate Cancer

2010 · Jay Magidson, Karl Wassmann · 11

Blood-based biomarkers of malignant melanoma by gene expression analysis

2008 · M Fujita, Jun‐ichi Fujita, et al. · Journal of Investigative Dermatology · 2

Blood mRNA signature to predict survival in patients with metastatic melanoma treated with tremelimumab.

2013 · Yvonne M. Saenger, Jay Magidson, et al. · Journal of Clinical Oncology · 1

Sensitivity and specificity of a whole-blood RNA transcript-based diagnostic test for the diagnosis of prostate cancer (CaP) compared with prostate-specific antigen (PSA) alone

2009 · R. W. Ross, D. Bankaitis-Davis, et al. · Journal of Clinical Oncology · 1

Data from Blood mRNA Expression Profiling Predicts Survival in Patients Treated with Tremelimumab

2023 · Yvonne Saenger, Jay Magidson, et al.

Data from Blood mRNA Expression Profiling Predicts Survival in Patients Treated with Tremelimumab

2023 · Yvonne Saenger, Jay Magidson, et al.

Supplementary Table 1 and 2 from Blood mRNA Expression Profiling Predicts Survival in Patients Treated with Tremelimumab

2023 · Yvonne Saenger, Jay Magidson, et al.

Figure S1 from Blood mRNA Expression Profiling Predicts Survival in Patients Treated with Tremelimumab

2023 · Yvonne Saenger, Jay Magidson, et al.

Figure S1 from Blood mRNA Expression Profiling Predicts Survival in Patients Treated with Tremelimumab

2023 · Yvonne Saenger, Jay Magidson, et al.

A validated whole-blood RNA transcript-based prognostic model that predicts survival in men with castration-resistant prostate cancer.

2012 · William K. Oh, Philip Kantoff, et al. · Journal of Clinical Oncology

Works count: 20

Citation count: 369

H-index: 7

I10-index: 7